Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children

Inclusion Criteria:

• Subjects who the investigator believes that their parents/ guardians can and will comply with the requirements of the protocol should be enrolled in the study.
• A male or female between, and including, 31 and 34 months of age at the time of the enrolment.
• Subjects who previously participated in study NCT00496015
• For the subjects in the primed AP-AP and NAP-pre groups: subjects who received a booster dose of the pneumococcal conjugate vaccine prior to the study amendment 3.
• For the subjects in the unprimed group: subjects who received a dose of the meningococcal vaccine GSK134612.
• Written informed consent obtained from the parent or guardian of the subject.
• Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding enrolment, or planned use during the entire study period.
• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during the entire study period.
• Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of study vaccine and ending 30 days after.
• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
• History of seizures or progressive neurological disease.
• Acute disease at the time of enrolment, defined as the presence of a mild, moderate or severe illness with or without fever.
• Administration or planned use of immunoglobulins and/ or any blood products during the entire study period.
• A family history of congenital or hereditary immunodeficiency.
• Major congenital defects or serious chronic illness.
• Subjects of which both parents have a history of atopia (polinosis, asthma, atopic eczema).
• Administration of any pneumococcal vaccine since the end of study NCT00496015.